Nkarta, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $162.6M
- Price
- $2.27
- % Change (Daily % change from the live per-ticker quote feed.)
- -1.73%
- Volume
- 566.5K
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Quick stats
Shares outstanding71.6M
Computed float50.0M
Float / shares69.8%
Cash runway (months)19.4
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001787400
Websitehttps://www.nkartatx.com
AI Summary
AI-generated1/13
minorneutralother
Nkarta to Participate in September Investor Conferences
Nkarta announced participation in two September investor conferences: a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026, and a fireside chat at the Stifel 2026 Virtual Immunology and Inflammation Forum on September 23, 2026.
Both events will be webcast simultaneously on Nkarta's investor relations website, with replays archived for approximately 90 days.
No new clinical data, guidance, or business updates were disclosed in this release; it is a routine IR calendar announcement for the clinical-stage autoimmune NK cell therapy developer.